Introduction
============

Worldwide, postpartum haemorrhage remains one of the leading causes of maternal mortality[@ref1] and the main component of severe morbidity,[@ref2] [@ref3] [@ref4] [@ref5] jeopardising women's fertility, exposing them to risks of transfusion and intensive care, and incurring costs. From reports in developed countries, about 1% of deliveries are associated with severe postpartum haemorrhage.[@ref3] [@ref4] [@ref5] [@ref6]

Decreasing the prevalence of severe postpartum haemorrhage remains a challenge. This seems all the more important given the recent increase in the incidence of postpartum haemorrhage reported in several developed countries.[@ref2] [@ref7] [@ref8] Individual risk factors have been described but they poorly predict the occurrence of postpartum haemorrhage.[@ref9] [@ref10] Interest has focused on care processes, as they are potentially amenable to change. Studies of maternal deaths show that most deaths due to postpartum haemorrhage involve delayed and substandard care in the diagnosis and management of blood loss.[@ref11] [@ref12] [@ref13] Similar findings were drawn from a population based study of severe non-lethal postpartum haemorrhage.[@ref14]

Delay in the diagnosis and treatment of postpartum haemorrhage may result from an underestimation of blood loss at delivery. Assessment of postpartum blood loss, particularly after vaginal birth, is recognised as difficult. Many studies found that visual estimates of peripartum blood loss are often inaccurate,[@ref15] [@ref16] [@ref17] [@ref18] [@ref19] [@ref20] [@ref21] showing an overestimation of blood loss at low volumes and an underestimation at larger volumes, the magnitude of underestimation typically increasing with the volume of haemorrhage.

We hypothesised that if blood loss is monitored and objectively measured by collection in a transparent plastic bag rather than by visual assessment, the response of a care giver will be triggered more rapidly when excessive blood loss occurs. Specifically, when bleeding is excessive but before haemorrhage has become catastrophic, appropriate management will take place without delay, so reducing the incidence of severe postpartum haemorrhage. A preliminary study has shown that a plastic collector bag constitutes a simple instrument for diagnosing haemorrhage in the delivery room.[@ref22] The impact of its use on health outcomes related to postpartum haemorrhage has, however, never been tested. Despite lacking evidence, the bag is routinely used in many maternity units in Belgium, France, Italy, and Portugal (European Union Project of Obstetric Haemorrhage Reduction: Attitude, Trial and Early Warning System (EUPHRATES) survey,[@ref23] unpublished data).

We evaluated the effectiveness of systematic use of a transparent plastic collector bag to measure postpartum blood loss after vaginal delivery in reducing the incidence of severe postpartum haemorrhage.

Methods
=======

We used a cluster randomised design with maternity unit as the unit of randomisation. Given the logistics of clinical practice on the delivery suite, contamination seemed to be inevitable in an individual patient randomised trial setting. The sites we selected for the trial comprised 78 maternity units in 13 European countries (table 1). Maternity units were eligible if they had more than 200 vaginal deliveries annually (excluding water births) and no previous policy for routine use of collector bags. In addition, to ensure that the standard of care for management of the third stage of labour was similar across all participating units, the units had to comply with the EUPHRATES consensus statement on the prevention and management of postpartum haemorrhage,[@ref24] a minimum standard, not a detailed guideline.

In all maternity units of participating countries except Denmark, we included all women undergoing a vaginal delivery during the study period. In Denmark, enrolment into the study in each maternity unit depended on the midwife; if a midwife agreed to participate, we included all of the vaginal deliveries that she or he took care of in their maternity unit.

The random allocation was produced centrally by the National Perinatal Epidemiology Unit, Oxford. A stratified design was used to ensure that the two arms of the trial were as similar as possible at baseline for the stratification factors of country and size of maternity unit (median split within country). The maternity units were randomly allocated to either systematic use of a collector bag after vaginal delivery (intervention arm) or no use of the bag (control group).

Intervention
------------

The trial was implemented between January 2006 and May 2007, depending on the country. Before participation, each centre was visited by the national coordinator. At the visit, staff were reminded of the EUPHRATES consensus statement on the prevention and management of postpartum haemorrhage and familiarised with the processes and the data collection instrument.

A second visit from the national coordinator took place in the intervention group after randomisation, when use of the collector bag was explained to birth attendants with the aid of standard written instructions and a training video. The bag was to be placed under the mother's pelvis as soon as the baby was born and before delivery of the placenta. The bag was transparent and graduated, allowing continuous monitoring of blood loss. It did not require sterilisation and could be used in the dorsal, lateral, or lithotomy positions. Women delivering standing or crouching could be offered the opportunity to lie down for the third stage, allowing the bag to be placed under their pelvis. The bag was to be left in situ until the birth attendant was no longer concerned about blood loss, such as when a sanitary towel was applied to the vulva. Bags were purchased centrally and provided to each cluster in the intervention arm.

No collector bag was used in the control group, with postpartum blood loss being assessed visually. The control group was monitored during the study period to assess compliance with allocation.

Outcomes
--------

The primary outcome was the incidence of severe postpartum haemorrhage after vaginal deliveries, defined as a composite of all women who experienced one or more of blood transfusion, intravenous plasma expansion, arterial embolisation, surgical procedure, admission to an intensive care unit, treatment with recombinant factor VII, and death. Secondary outcomes were each of the components of the primary outcome, manual removal of the placenta, and administration of prostaglandins after delivery.

Data collection
---------------

Each participating centre was asked to collect data for four months from all women who had had a vaginal delivery: for one month before randomisation (baseline period) and for three months after randomisation in the control group (trial period). The three month period of data collection in the intervention group followed a two week training period during which the unit started using the collector bag.

Data were collected using a form filled in by the birth attendants for each vaginal delivery. Information was collected on maternal age, induction of labour, mode of delivery, number of babies, birth weight, use of prophylactic uterotonics, and outcome data. A second form was used for deliveries with severe postpartum haemorrhage, with information collected on the delivery and management of postpartum haemorrhage. This form was used to cross check criteria for the primary outcome.

Sample size
-----------

The sample size calculation took into account the cluster randomised design; we estimated the intracluster correlation coefficient to be 0.01. With the assumption of an event rate for the primary outcome of 2.5% in the control group, 82 clusters (41 in each arm of the trial) were required to detect a decrease in the event rate to 1.5% (a 40% relative risk reduction) with 80% power, a two sided significance level of 5%, and an average cluster size of 300 women.[@ref25]

Statistical analysis
--------------------

The participants and maternity units were analysed in the groups to which they were assigned regardless of the management received by individual women or deviation from the protocol.

We summarised the baseline characteristics of the maternity units and individual women using counts (percentages) for categorical variables, means (standard deviations) for normally distributed continuous variables, or medians (interquartile ranges) for other continuous variables. Comparative statistical analysis was done at both individual and cluster level and took into account the effect of clustering. All statistical tests were two sided (5% significance level) and not adjusted for multiple comparisons. Statistical analyses were done using SPSS version 17 and Stata v10.0 software.

For analysis at the individual level we compared primary and secondary outcomes between the two study groups both unadjusted and adjusted for the effect of clustering. To determine the magnitude and direction of any differences in outcomes between the two groups, we calculated crude odds ratios and 95% confidence intervals. We also used logistic regression to adjust for clustering and key prognostic factors. The cluster randomised design imparts a data structure that facilitates the calculation of a valid intracluster correlation coefficient, ρ.

Cluster level analysis was carried out only on the primary outcome. Some hospitals contributed fewer events than others and some recruited fewer women. We allowed these hospitals to have less effect on the treatment estimate by weighting the analysis on the basis of the precision---that is, we calculated the weighted mean difference for the treatment comparison. We used a weighted linear regression model to test the effect of the intervention on the rate of severe postpartum haemorrhage during the trial period, adjusting for the baseline rate, expressed as the weighted mean difference (95% confidence interval).

Results
=======

Figure 1[](#fig1){ref-type="fig"} shows the flow of maternity units and women through the study. Of the 84 maternity units meeting the inclusion criteria, two declined to participate before allocation. Overall, 41 maternity units were randomised to the intervention group and 41 to the control group. Two maternity units in each group opted out before receiving notification of allocation owing to lack of necessary resources. Thirty nine in each group completed the trial. Table 1[](#tbl1){ref-type="table"} shows the number of participating maternity units and women included in each country.

![**Fig 1** Flow diagram of trial](zhaw689547.f1_default){#fig1}

###### 

 Number of maternity units and women in baseline and trial periods by allocation and by country\*

  Country       Maternity units        Women                                                         
  ------------- ----------------- ---- ------- -------------- ------ ------ ------ -------- -------- --------
  Austria       3                 3            1067 (3.0)     371    219    152    696      359      337
  Belgium       8                 8            6013 (17.1)    1552   728    824    4461     1867     2594
  Denmark       3                 3            1657 (4.7)     507    272    235    1150     562      588
  Finland       2                 2            4805 (13.7)    1347   656    691    3458     1551     1907
  France        3                 3            3702 (10.6)    972    544    428    2730     1351     1379
  Hungary       4                 4            2230 (6.4)     562    268    294    1668     784      884
  Ireland       2                 2            3971 (11.3)    950    300    650    3021     946      2075
  Italy         3                 3            926 (2.6)      196    138    58     730      491      239
  Netherlands   1                 1            1084 (3.1)     301    130    171    783      322      461
  Norway        1                 1            668 (1.9)      143    72     71     525      241      284
  Portugal      2                 3            3274 (9.3)     810    338    472    2464     901      1563
  Spain         4                 3            4351 (12.4)    1595   1097   498    2756     1239     1517
  Switzerland   3                 3            1328 (3.8)     389    175    214    939      423      516
  Total         39                39           35 076 (100)   9695   4937   4758   25 381   11 037   14 344

\*Baseline data were unavailable in one maternity unit in intervention group.

One maternity unit in the intervention group did not collect baseline data. Deviating from the protocol, most maternity units (31 of 39) continued collecting data during the two week training period in the intervention arm. In these units, trial data collection started after the first month of baseline data collection. Four units in the control group collected trial data for more than three months (up to five months). Only the three month period of data collection specified in the protocol was considered for all units. In some Austrian hospitals the number of women included was low, given the total expected number of deliveries. The national coordinator confirmed that the missing data were all caesarean deliveries and that in some hospitals the caesarean rate was high. Nevertheless, sensitivity analyses were carried out and showed that the results were not influenced by excluding these hospitals or even the entire Austrian dataset.

Baseline data were collected for 4937 vaginal deliveries in the intervention group and 4758 in the control group. The characteristics of the maternity units and women (table 2[](#tbl2){ref-type="table"}) in both groups were broadly similar for all factors except manual removal of the placenta and use of prophylactic uterotonics, which were more common among women in the intervention group.

###### 

 Baseline characteristics of maternity units and individual women by allocation. Values are numbers (percentages) unless stated otherwise

  Characteristics                                                Intervention group (n=38)\*   Control group (n=39)
  -------------------------------------------------------------- ----------------------------- ----------------------
  Maternity units:                                                                             
   Median (interquartile range) rate of caesarean delivery (%)   21.1 (17.4-26.6)              21.7 (14.6-26.0)
   \>1600 deliveries annually                                    20 (52.6)                     19 (48.7)
  Maternal age (years):                                          (n=4937)                      (n=4758)
   Mean (SD)                                                     29.6 (5.4)                    29.7 (5.5)
   Median (interquartile range)                                  30.0 (26-33)                  30.0 (26-33)
   No with missing data                                          31                            23
  Mode of delivery:                                                                            
   Spontaneous vaginal                                           4104 (83.1)                   4062 (85.4)
   Operative vaginal                                             833 (16.9)                    696 (14.6)
  Induction                                                      1080 (21.9)                   1043 (21.9)
  No of babies:                                                                                
   Single                                                        4833 (98.5)                   4645 (98.6)
   Multiple                                                      76 (1.5)                      68 (1.4)
   No with missing data                                          28                            45
  Birth weight (g):                                                                            
   Mean (SD)                                                     3315 (566.4)                  3349 (549.1)
   Median (interquartile range)                                  3330 (3020-3660)              3370 (3050-3690)
   No with missing data                                          26                            29
  Prophylactic uterotonics in 3rd stage:                         3527 (71.4)                   3153 (66.3)
   No with missing data                                          0                             5
  Prostaglandin used after birth:                                212 (4.3)                     218 (4.6)
   No with missing data                                          0                             5
  Manual removal of placenta:                                    204 (4.1)                     121 (2.5)
   No with missing data                                          0                             5
  Severe postpartum haemorrhage†                                 60 (1.22)                     90 (1.89)

\*Baseline data unavailable in one maternity unit.

†One of following: maternal death, transfusion, plasma expansion, surgery or embolisation, admission to intensive care unit, or treatment with recombinant factor VII.

Primary outcome
---------------

### Individual level analysis

A total of 25 381 women were included in the analysis (11 037 in the intervention group, 14 344 in the control group). The greater number of women in the control group resulted from a larger median cluster size (241 in the intervention group, 284 in the control group).

The incidence of severe postpartum haemorrhage was 189 of 11 037 vaginal deliveries (1.71%) in the intervention group compared with 295 of 14 344 in the control group (2.06%). The difference was not statistically significant (table 3[](#tbl3){ref-type="table"}). The crude odds ratio for the effect of the intervention was 0.83 (95% confidence interval 0.69 to 1.00). The odds ratio adjusted for clustering was 0.83 (0.27 to 2.60); after further adjustment for maternal age, use of prophylactic uterotonics in the third stage, mode of delivery, and birth weight, the odds ratio was 0.82 (0.26 to 2.53). Sensitivity analyses were done to test the robustness of this result excluding units that deviated from the protocol, and also by country and baseline rate of severe postpartum haemorrhage (median split by country). The results of these analyses were similar.

###### 

 Main outcomes. Values are numbers (percentages) unless stated otherwise

  Outcomes                              Intervention (n=11 037)   Control (n=14 344)   ICC (ρ)   Crude odds ratio (95% CI)      Adjusted odds ratio (95% CI)†   Adjusted odds ratio (95% CI)‡
  ------------------------------------- ------------------------- -------------------- --------- ------------------------------ ------------------------------- -------------------------------
  Primary outcome:                                                                                                                                              
   Severe postpartum haemorrhage\*      189 (1.71)                295 (2.06)           0.023     0.83 (0.69 to 1.00), P=0.05    0.83 (0.27 to 2.60), P=0.8      0.82 (0.26 to 2.53), P=0.7
  Secondary outcomes:                                                                                                                                           
   Blood transfusion                    86 (0.78)                 135 (0.94)           0.011     0.83 (0.63 to 1.68), P=0.2     0.83 (0.35 to 1.96), P=0.8      0.80 (0.33 to 1.90), P=0.6
   Plasma expander                      127 (1.15)                222 (1.55)           0.022     0.74 (0.59 to 0.92), P=0.007   0.74 (0.20 to 2.72), P=0.7      0.95 (0.62 to 1.46), P=1.0
   Surgical procedure or embolisation   50 (0.45)                 76 (0.53)            0.012     0.85 (0.60 to 1.22), P=0.9     0.85 (0.20 to 3.63), P=0.9      0.78 (0.18 to 3.40), P=0.7
   Manual removal of placenta           326 (2.95)                366 (2.55)           0.016     1.16 (1.00 to 1.35), P=0.05    1.16 (0.76 to 1.77), P=0.5      1.09 (0.72 to 1.67), P=0.7
   Prostaglandins                       501 (4.54)                766 (5.34)           0.129     0.84 (0.75 to 0.95), P=0.004   0.84 (0.40 to 1.77), P=0.7      0.85 (0.40 to 1.80), P=0.7

ICC=intracluster correlation coefficient.

\*Defined by one of following: maternal death, transfusion, plasma expansion, surgery or embolisation, admission to intensive care unit, or treatment with recombinant factor VII.

†Adjusted for clustering (maternity unit).

‡Adjusted for clustering (maternity unit), age of mother, prophylactic uterotonics used in third stage, mode of delivery, and birth weight.

### Cluster level analysis

The weighted mean rate for severe postpartum haemorrhage was 1.71% (SD 2.51%) in the intervention group and 2.06% (SD 3.52%) in the control group. The intracluster correlation coefficient for severe postpartum haemorrhage was 0.023. The rate of severe postpartum haemorrhage did not differ significantly between the groups: weighted mean difference −0.34% (95% confidence interval −2.56% to 1.87%); P=0.75. Adjusting for the baseline rate of severe postpartum haemorrhage resulted in a slight change in this result: adjusted weighted mean difference 0.16% (−0.69% to 1.02%); P=0.70. Rates of severe postpartum haemorrhage in the baseline and trial periods for each maternity unit were heterogeneous across units in different countries (fig 2[](#fig2){ref-type="fig"}).

![**Fig 2** Rate of severe postpartum haemorrhage during baseline and trial periods for each maternity unit. Each dot represents one maternity unit. Diagonal line denotes no change in rate of postpartum haemorrhage from baseline to trial period](zhaw689547.f2_default){#fig2}

Figure 3[](#fig3){ref-type="fig"} shows the difference in baseline and trial rates of severe postpartum haemorrhage for each unit in the intervention group, according to compliance with bag use. No relation was found between the difference in severe postpartum haemorrhage rates (baseline and trial) and the proportion of bag use. Analysis of the intervention effect on the primary outcome, including in the intervention arm only maternity units where the bag was used in at least 50% of vaginal deliveries, showed no significant difference between the two groups: individual level analysis adjusting for cluster and individual characteristics, adjusted odds ratio 0.59 (95% confidence interval 0.23 to 1.53).

![**Fig 3** Difference in rate of severe postpartum haemorrhage (baseline rate−intervention rate) according to compliance with intervention (percentage of women with measured blood loss) in 38 units in intervention group during trial](zhaw689547.f3_default){#fig3}

Secondary outcomes (individual level analysis)
----------------------------------------------

Analyses were done to test the effect of the intervention on the main components of the primary outcome (table 3). The proportion of women who had blood transfusion, surgical procedure, embolisation, or manual removal of placenta did not substantially differ between the intervention and control groups, whether after adjustment for cluster or after further adjustment for other prognostic factors. No maternal deaths occurred.

The proportion of women in receipt of intravenous plasma expanders or prostaglandins differed between intervention and control groups, but the differences were not significant after adjustment for clustering effect.

Discussion
==========

In this cluster randomised trial of 25 381 vaginal deliveries in 78 maternity units of 13 European countries, the systematic use of a collector bag after vaginal delivery did not modify the rate of severe postpartum haemorrhage. There was no evidence of heterogeneity, the results not differing by country or size of hospital.

Strengths and limitations of the study
--------------------------------------

This trial provides new results on an unexplored although controversial aspect of care in the third stage of labour. Although objective measurement has been shown to increase the accuracy of assessing postpartum blood loss compared with visual estimation,[@ref15] [@ref16] [@ref17] [@ref18] [@ref19] [@ref20] [@ref21] the routine use of a collector bag was not associated with a significant decrease in severe postpartum haemorrhage. This result constitutes an important contribution to the ongoing debate on strategies to improve the care of women with postpartum haemorrhage and to decrease the incidence of severe cases. Additionally, the cluster randomised design and the large number of clusters and their diversity provide good external validity to this trial. Small deviations from the protocol did occur for data collection, but sensitivity analyses showed that none of these changed the internal validity of the trial.

Heterogeneity of baseline rates for severe postpartum haemorrhage was large between maternity units (0% to 13.4%). In theory such a variation should be an asset and reflect a broad range of levels of risk in the participating maternity units. Because these differences were strongly related to the country, however, some concern remains about the criteria in use for the management of postpartum haemorrhage in different parts of Europe. Sensitivity analysis showed that this aspect did not alter the results.

Baseline data showed some heterogeneity between the intervention and control groups. Heterogeneity in postpartum haemorrhage related practices and rates has been reported across maternity units in Europe, both between and within countries.[@ref4] [@ref23] Randomisation should balance these differences between the two arms. However, given the number of units randomised, although large for a cluster randomised controlled trial, there is a slight possibility of residual imbalance. Analyses were, however, adjusted for the main determinants of postpartum haemorrhage (individual level analysis) and baseline rate of severe postpartum haemorrhage (cluster level analysis); in addition, sensitivity analysis indicated that the absence of a major effect of the intervention was similar whether the maternity units had a high or low baseline rate of severe postpartum haemorrhage. In consequence, any perceived or real imbalance in these characteristics should have little or no effect on the findings.

Hypotheses for the results
--------------------------

Different mechanisms may explain the absence of difference in the rates of severe postpartum haemorrhage between maternity units that used the bag and those that visually assessed blood loss. This may result from a lack of compliance to the intervention. This is, however, unlikely because of the persistent absence of difference between the two groups when the analysis was restricted to those maternity units that used the bag in a high proportion of deliveries.

One potential reason for the apparent ineffectiveness of the intervention might be incorrect use of the bags; in particular, that they were covered most of the time and thus could not be viewed. Such misuse is unlikely to explain the observed lack of effect as detailed oral and written instructions were provided and the training video clearly showed the care giver watching the bag and the graduations.

Participation in the study may indicate a particular interest in the management of postpartum haemorrhage so that existing management had little room for improvement. Such a selection process is, however, unlikely in these maternity units, owing to the variety of baseline rates of severe postpartum haemorrhage.

It may be hypothesised that the intervention has a double effect, in two opposite directions: increasing the rate of ascertainment through increased vigilance and decreasing the prevalence through timely management of excessive bleeding. If these two components were of the same order of magnitude, the global effect would be no effect. If this explanation was realistic, however, different effect sizes would be expected with different baseline rates or different degrees of compliance, or both. None of this occurred, making it unlikely that a benefit of the intervention in terms of decreased severe outcome was balanced by an equivalent increase in ascertainment. In fact the intervention seemed to increase the rates of postpartum haemorrhage, reflecting that the intervention was possibly more effective in improving ascertainment than in changing practice.

A concomitant effect in the control group may also have contributed to the absence of difference between the two arms. Contamination of the intervention to control units is unlikely since participating units were not in contact, and no use of bags was reported in all the control maternity units. Participation in a research study, independently of any specific intervention, has been reported to change behaviours of participants (Hawthorne effect).[@ref26] The hypothesis that the management of postpartum haemorrhage would have improved in the control arm is, however, not supported by the absence of change in the rate of severe postpartum haemorrhage between the baseline and trial periods in this group.

The most plausible explanation of the negative result of this trial is that having a more accurate assessment of postpartum blood loss is not by itself sufficient to change behaviours of care givers and improve the management of postpartum haemorrhage. Lack of identification of women with excessive postpartum bleeding is a problem, potentially leading to higher levels of medical intervention if the bleeding progresses to severe haemorrhage. We designed a strategy to increase the awareness of care givers. The fact that this has not translated into a change in clinical outcomes probably reflects the complexity of decisions on management, which are influenced by multiple factors such as organisation of the delivery ward and how care givers perceive and cope with emergencies.

Comparison with other studies
-----------------------------

We did not find any other published study assessing the effectiveness of the collector bag. We have, however, identified other large multicentre randomised trials in the specialty of maternal and child health where a diagnostic or screening test was evaluated but without any associated instructions about the management of abnormal results.[@ref27] [@ref28] [@ref29] None of these trials showed benefit with the introduction of the test. In addition one study showed that simple information is not sufficient to have an effect on the readiness of birth attendants to change.[@ref30] These various reports suggest that the effect of enhanced diagnostic methods should include an accompanying protocol of management and may be a specific behavioural intervention, which in effect becomes a "complex intervention."

Policy implications
-------------------

The practical implication of these results for high income countries is that those units that are using a collector bag (cost per bag between €1 (88p; \$1.44) and €11 in Europe) need to reconsider their practice and possibly reallocate the resources to other aspects of care. Units that are not routinely using the bag should keep the same policy. For resource poor countries, positive results with the use of the "kanga collector" have been reported.[@ref31] This needs to be tested in a randomised design. In the current context of reported ongoing increase in the prevalence of postpartum haemorrhage, further research is needed to develop and test effective strategies to decrease the prevalence of severe postpartum haemorrhage through improvement of management. These will probably be multifaceted interventions, and in this context the collector bag may warrant further investigation.

### What is already known on this topic

1.  Delay in the diagnosis and initial care of postpartum haemorrhage has been reported and may result from visual underestimation of blood loss

2.  A collector bag has been proposed as a useful tool to measure blood loss but has not been tested despite being used routinely in many maternity units in Europe

### What this study adds

1.  The incidence of severe postpartum haemorrhage was not reduced by routine use of a collector bag to objectively measure postpartum blood loss after vaginal delivery, without specific guidelines on threshold and action
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